The preliminary conference programme is as follows, subject to change. Download at-a-glance version here.

Sunday 14 July 2019

11:30 - 13:30 Delegate Registration

13:30 - 15:00 Session 1: Welcome and Keynote Talk

13:30 - 14:00 Welcome and Opening Remarks

Professor Rob Bristow & Dr Natalie Cook

14:00 - 15:00 Opening Keynote Lecture
Dr Lillian Siu (Princess Margaret Hospital, Canada)
"Phase I: past and present"

15:00 - 15:30 Coffee break

15:30 - 17:00 Session 2: Debate Session

Chair: Professor Rob Bristow

The Big Debate: “This house believes every cancer patient should have comprehensive genomic profiling prior to each experimental therapy”

Debate leads: Professor Jeff Evans (Beatson Institute, UK) and Dr Tim Yap (MD Anderson, USA)


Monday 15 July 2019

09:00 - 10:30 Session 3: Novel targets and their impact on trial designs

Chairs: Professor Duncan Jodrell and Dr Louise Carter

Professor Caroline Springer (Cancer Research UK Manchester Institute, UK)
"CRUK Manchester Institute Drug Discovery Unit: Emerging Targets in Drug Development"

Professor Ruth Plummer (University of Newcastle, UK)
"Rare targets and their impact on the evolution of trial design"

Professor Sarah Blagden (University of Oxford, UK)
"Challenges of delivering platform based trials"

Professor Pamela Munster (UCSF, USA)
"Novel targets in epigenetics"

10:30 - 11:00 Coffee break

11:00 - 12:30 Session 4: Precision Medicine

Chairs: Dr Matt Krebs, Professor Richard Marais

Professor Caroline Dive (Cancer Research UK Manchester Institute, UK)

Professor Gary Middleton (University of Birmingham, UK)

Professor Steven Jones (Michael Smith Genome Sciences Centre, BC Cancer, Canada)
"Using genomics and transcriptomics to develop precision medicine in oncology in British Columbia.”


12:30 - 13:30 Lunch



13:30 - 14:30 Session 5: Keynote

Professor Skip Burris (Sarah Cannon Research Institute, USA)
“Next steps for phase I”

14:30 - 15:00 Coffee break

15:00 - 16:30 Session 6: Immuno-oncology

Chairs: Dr Anne Armstrong, Dr Elaine Kilgour, Professor Tracy Hussell

15:00 - 15:30 Dr Santiago Zelanay (CRUK Manchester Institute, UK)
"Manipulating inflammation to raise cancer immunogenicity"

15:30 - 16:00 Dr Stefan Symeonides (University of Edinburgh, UK)
"Combination studies - immunotherapies and other targeted agents”

16:00 - 16:30 Dr Charles Ferté (MedImmune)


19:00 - Conference Dinner, Science and Industry Museum (SIM)


Tuesday 16 July 2019

09:00 - 12:30 PARALLEL NURSING WORKSHOP - more information here

09:00 - 10:30 Session 7: Radiotherapy combinations

Chairs: Professor Tim Illidge, Professor Kaye Williams

09:00 - 09:30 Professor Kaye Williams (The University of Manchester, UK)

09:30 - 10:00 Professor Anthony Chalmers (University of Glasgow, UK)

10:00 - 10:30 Professor Dave Raben (University of Colorado, USA)

10:30 - 11:00 Coffee break

11:00 - 12:30 Session 8: Advanced Therapies

Chairs: Dr Fiona Thistlethwaite, Professor Robert Hawkins

11:00 - 11:30 Professor Brian Bigger (The University of Manchester, UK)
"Developing stem cell gene therapies for childhood dementias"

11:30 - 12:00 Dr Sophie Papa (King's College London, UK)
"CAR T cells and solid tumours: efficacy, toxicity and practicality"

12:00 - 12:30 Dr Reno Debets (Erasmus Medical Centre, Netherlands)
"T cells engineered with MAGE-C2 TCR to treat patients with melanoma and head-and-neck cancer: a 2019 trial in Rotterdam"

12:30 - 13:30 Lunch and poster session 

13:30 - 15:00 Session 9: Trial Design Methodology

Chairs: Professor Andrew Hughes, Professor Caroline Dive

13:30 - 14:00 Question 1

Do rules based designs offer better value (in time, cost and identifying the recommended phase II dose range(s) than model-based designs?

Percy Ivy (National Cancer Institute, USA): This conference believes that "rules based" designs offer better value

Adrian Mander (University of Cambridge, UK): This conference believes that "model based" designs offer better value

14:00 - 14:30 Question 2

How can we bring phase I into the digital age?

Donal Landers (Cancer Research UK Manchester Institute): Can the patients ever become co-scientists with us in the trial?

Steffan Stringer (Foundry Health, UK): Can Investigator sites ever become digital hubs?

14:30 - 15:00 Question 3

What is the primary purpose of phase I?

Udai Banerji (ICR, London, UK): The primary purpose is to define a recommended dose range for phase 2

Glen Clack (University of Sheffield, UK): The primary purpose is to achieve drug registration through modular trial designs

Session 10: Closing Remarks Professor Andrew Hughes